2. Search Result
Search Result
Results for "

biliary tract cancer

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

4

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P991564
    Arcotatug

    IBI-343 antibody; HB37A6; TAK-921 Antibody

    		 ADC Antibody Claudin Cancer
    Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .
    Arcotatug
  • HY-P990059
    Puxitatug

    INT-016; AZD8205 Antibody

    		 ADC Antibody CD276/B7-H3 Cancer
    Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .
    Puxitatug
  • HY-201296A
    Tauroursocholic acid sodium

    TUCA sodium

    		 Drug Isomer Cancer
    Tauroursocholic acid (TUCA) sodium is a taurine-conjugated form of the bile acid ursocholic acid and the 7β-hydroxy epimer of Taurocholic acid (HY-B1788). Tauroursocholic acid sodium exists in abundance during the biliary tract cancer, disrupting the balance and cellular toxicity of bile acids and inducing carcinogenesis through oxidative DNA damage and DNA mutation. Tauroursocholic acid (TUCA) sodium can be used for biliary tract cancer research .
    Tauroursocholic acid sodium
  • HY-P992021
    WM-A1-3389

    		Transmembrane Glycoprotein Cancer
    WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer .
    WM-A1-3389
  • HY-P992454
    S095018

    		Tim3 Cancer
    S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 + T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .
    S095018
  • HY-183947
    4-Bromolevamisole

    		Phosphatase Drug Derivative Cancer
    4-Bromolevamisole, an analogues of Levamisole (HY-A0106), is a phosphatase inhibitor. 4-Bromolevamisole potentiates the antineoplastic activity of 5-Fluorouracil (HY-90006), its analogues, or prodrugs thereof.4-Bromolevamisole can be used for cancer research .
    4-Bromolevamisole

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: